SkinBioTherapeutics (LON:SBTX) Shares Down 23.1% – Should You Sell?

SkinBioTherapeutics plc (LON:SBTX) shares fell 23.1% on Friday . The company traded as low as GBX 12.77 and last traded at GBX 15. 2,636,007 shares were traded during trading, an increase of 80% from the average session volume of 1,466,438 shares. The stock had previously closed at GBX 19.50.

SkinBioTherapeutics Trading Down 30.8%

The firm has a 50 day moving average of GBX 17.26 and a 200-day moving average of GBX 16.17. The firm has a market capitalization of £34.95 million, a P/E ratio of -43.55 and a beta of 2.01. The company has a quick ratio of 10.01, a current ratio of 0.93 and a debt-to-equity ratio of 27.57.

SkinBioTherapeutics (LON:SBTX) last released its earnings results on Monday, December 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.